SCHEDULE 13G: Intracoastal Capital and Affiliates Disclose 5.5% Passive Stake in Imunon, Inc.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has reported a passive beneficial ownership of 5.5% in Imunon, Inc. common stock.

Summary

• The filing identifies Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC as the Reporting Persons.
• The Reporting Persons collectively hold beneficial ownership of 1,111,112 shares of Imunon, Inc. common stock.
• This ownership represents approximately 5.5% of the total outstanding common stock of Imunon, Inc.
• The calculation of the percentage is based on 17,541,732 shares outstanding on May 16, 2025, plus an additional 2,777,779 shares of Common Stock issued at the closing of a Securities Purchase Agreement (SPA) on May 28, 2025.
• All 1,111,112 shares are held with shared voting and shared dispositive power among the Reporting Persons.
• The filing explicitly excludes 2,222,224 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1.
• The exclusion of warrant shares is due to a blocker provision limiting beneficial ownership to 4.99% and the requirement for stockholder approval for exercisability.
• If the blocker provision were not in place and the warrant was currently exercisable, the beneficial ownership would be 3,333,336 shares.
• The Reporting Persons certify that the securities were not acquired for the purpose of changing or influencing the control of Imunon, Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant passive investment by a group, suggesting confidence in the company. The investment is part of a structured transaction (SPA) which likely provided capital to the company. The passive nature (13G) means no immediate control changes are intended, which is generally neutral to positive for existing shareholders. The warrant provides potential for future investment.

Positives

• The disclosure of a significant 5.5% passive stake by a group of investors, including Intracoastal Capital LLC, can signal external confidence in Imunon, Inc.'s long-term prospects.
• The investment stems from a Securities Purchase Agreement (SPA), indicating a structured transaction that likely provided capital to the company.

Negatives

• No immediate negatives are apparent from this passive Schedule 13G filing, which primarily serves as a disclosure of ownership.

Risks

• The exercisability of Intracoastal Warrant 1, which would result in an additional 2,222,224 shares, is contingent on stockholder approval, introducing a potential uncertainty or delay in the full realization of the investment.
• The 4.99% blocker provision within Intracoastal Warrant 1 limits the immediate beneficial ownership percentage, preventing the holder from exceeding this threshold without specific conditions being met, which could restrict the investor's flexibility.

Future Outlook

The document does not provide forward-looking statements or guidance from Imunon, Inc. itself. However, it indicates that the full exercisability of Intracoastal Warrant 1, which would increase the beneficial ownership, is contingent on future stockholder approval.

Management Comments

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This Schedule 13G filing indicates a new significant passive investor in Imunon, Inc., a biotechnology company. Such investments, especially when stemming from a Securities Purchase Agreement, are common in the biotech industry for funding research and development, clinical trials, and general corporate purposes. The acquisition of a substantial stake by an external investment group can be interpreted as a vote of confidence in the company's strategic direction or pipeline.

Comparison to Industry Standards

• A 5.5% passive stake is a standard threshold for triggering a Schedule 13G filing, indicating a significant but non-controlling investment, consistent with typical institutional investor behavior.
• The use of a Securities Purchase Agreement (SPA) combined with warrants is a common financing mechanism for growth-stage companies, particularly in the life sciences sector, to raise capital from institutional investors.
• The inclusion of a blocker provision, such as the 4.99% limit on warrant exercisability, is a standard practice in capital raises to prevent the investor from exceeding certain ownership thresholds (e.g., 5%, 10%, 20%) that would trigger additional regulatory filings (like Schedule 13D) or corporate governance implications (like shareholder approval requirements for exceeding 20% ownership).

Stakeholder Impact

• Shareholders: The filing indicates a new significant shareholder group, potentially increasing investor confidence. The issuance of new shares (2,777,779) as part of the SPA would dilute existing shareholders, which is typical for capital raises. The potential future exercise of the warrant would lead to further dilution.

Next Steps

• Stockholder approval will be required for the issuance of shares upon the exercise of Intracoastal Warrant 1.

Key Dates

Recommendation

Keywords

Imunon Inc, IMUN, Schedule 13G, Beneficial Ownership, Passive Investment, Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher, Common Stock, SEC Filing, Securities Purchase Agreement, Warrant, Shareholder Stake